CXCL12 and acute myeloid leukemia: However, de novo AML MSC presented a significant increase in expression levels of vascular endothelial growth factor A (VEGFA), stromal cell-derived factor 1 (CXCL12), receptor of prostaglandin E2 (RPGE2), indoleamine 2,3-dioxygenase (IDO), IL6 and IL32 (all p < 0.05), followed by a decrease in IL10 expression (p = 0.009) when compared to the HC group.